Clinical Trial Update: Multicenter Study of Rociletinib Administered to Patients With Previously Treated Mutant EGFR Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 multicenter trial of rociletinib in patients with previously treated mutant EGFR non-small cell lung cancer (terminated; results posted).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• rociletinib (rociletinib)

Snippet

Sponsor: Clovis Oncology, Inc. | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: TERMINATED | Results posted: 2020-08-12